Objective

To assess whether erenumab influences cerebral vasomotor reactivity and flow-mediated dilation in migraine patients.

Methods

Consecutive migraineurs prescribed erenumab at our Headache Centre and age and sex-matching controls were invited to participate in this observational longitudinal study. Patients were evaluated for cerebral vasomotor reactivity to hypercapnia (breath-holding index) in middle and posterior cerebral arteries and for brachial corrected flow mediated dilation at baseline (T0), after 2 weeks from the first erenumab injection (T2) and after 2 weeks from the fourth Erenumab injection (T18). Patients displaying a reduction of at least 50% in monthly migraine days after completing the fourth month of therapy were classified as responders.

Results

Sixty patients and 25 controls agreed to participate. Middle and posterior cerebral artery mean flow velocities, breath-holding index and flow-mediated dilation did not differ at T0 and from T0 to T2 in patients and controls. In patients, we neither observed a variation of the explored variables from T0 to T18 nor an interaction between evaluation times (T0–T2 or T0–T18) and chronic condition at T0, responder state or erenumab fourth dose.

Conclusions

Our findings demonstrate that erenumab preserves cerebral vasomotor reactivity and flow-mediated dilation in migraineurs without aura.

中文翻译：

---

Erenumab 不会改变无先兆偏头痛的脑血流动力学和内皮功能。

客观的

评估 erenumab 是否影响偏头痛患者的脑血管舒缩反应性和血流介导的扩张。

方法

连续偏头痛患者在我们的头痛中心开出了 erenumab，年龄和性别匹配的对照组被邀请参加这项观察性纵向研究。在基线 (T0)、首次注射 erenumab 2 周后 (T2) 和注射 2 周后，评估患者对大脑中动脉和后动脉高碳酸血症（屏气指数）的脑血管舒缩反应性和肱动脉校正血流介导的扩张。第四次 Erenumab 注射 (T18)。在完成第四个月的治疗后，每月偏头痛天数减少至少 50% 的患者被归类为反应者。

结果

60 名患者和 25 名对照组同意参与。大脑中动脉和后动脉的平均流速、屏气指数和血流介导的扩张在 T0 和 T0 到 T2 时在患者和对照组中没有差异。在患者中，我们既没有观察到从 T0 到 T18 的探索变量的变化，也没有观察到评估时间（T0-T2 或 T0-T18）与 T0 时的慢性状况、反应者状态或第四剂 erenumab 之间的相互作用。

结论

我们的研究结果表明，erenumab 保留了无先兆偏头痛患者的脑血管舒缩反应性和血流介导的扩张。